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Abstract 
Cannabis is becoming increasingly present in our society. In recent years, the line between the 
natural (cannabis) and the synthetic (synthetic cannabinoids), the recreational (cannabis) and the 
medical (pharmaceutical cannabinoids and medical cannabis) has been crossed. In this paper we 
review some of the novel aspects of cannabis and cannabinoids in relation to their legal situation, 
changes in their composition and forms of cannabis use, the concept of medical cannabis, and 
synthetic cannabinoids as new psychoactive substances (NPS). We have also analyzed serious 
adverse reactions and intoxications associated with the use of synthetic cannabinoids, as well as the 
latest developments in the research of pharmaceutical cannabinoids. 
Key words: Cannabis, Delta-9-tetrahydrocannabinol (THC), Cannabidiol (CBD), Medical cannabis; Synthetic 
cannabinoid 
1. Introduction 
In number of users, cannabis is the first illegal 
drug, and the third one if tobacco and alcohol are 
taken into account. Cannabis is increasingly present in 
our society both for its recreational (natural cannabis 
and synthetic cannabinoids) and medical use 
(pharmaceutical cannabinoids and medical cannabis). 
In 2015, an estimated 183.3 million people aged 15-64 
years used cannabis (3.8% of global population) [1]. 
Cannabis use is most prevalent among young people 
ages 15 to 34 (13.9 % using in the past year)[2]. Among 
15 to 16 year-old school students in Europe and 
United States last month cannabis use was 8% and 
15%, respectively [3]. 
In recent years, natural preparations with 
user-tailored compositions and new synthetic 
cannabinoids with high pharmacological potency 
have appeared. The line between the natural and the 
synthetic has been crossed. In this paper we review 
some of the novel aspects of cannabis and 
cannabinoids in relation to their legal situation, 
changes in their composition and forms of use, the 
concept medical cannabis, the synthetic cannabinoids 
as new psychoactive substances (NPS) and the serious 
adverse reactions and intoxications after their use. 
2. Cannabis  
2.1. Use of cannabis and its derivatives: legal 
aspects  
The legal status of cannabis continues to be 
highly controversial. Cannabis, its resin, extracts and 
tinctures are included in the I and IV United Nations 
Schedules of the 1961 Single Convention on Narcotic 
Drugs, and therefore they are subject to international 
control. Delta-9-tetrahydrocannabinol (THC) (isomers 
and stereochemical variants) and dronabinol 
(synthetic THC) are classified as psychotropic 
substances according to annexes I and II of the 1971 
United Nations Convention on Psychotropic 
Substances, respectively [4, 5]. Despite its 
classification, control measures differ between 








consumption offences and, consequently, in the 
application of administrative sanctions and/or 
penalties. Thus, in countries like the United States of 
America (USA) legal medical cannabis use is 
spreading in many states (29 states and districts) and 
recreational use is already allowed in seven of them 
(Alaska, California, Colorado, Maine, Massachusetts, 
Oregon, Washington, and Washington, D.C.). In 
Canada, cannabis is legal in only for medicinal 
purposes from early 2018, and on October 17, 2018, 
cannabis will be legal for recreational use [6]. In 
Europe, unlike the USA, the therapeutic use of 
cannabis is only legal in the Netherlands, Germany 
and Italy [7], although there are initiatives for 
approval in other countries. In South America, 
medical cannabis is legal in Uruguay and there are 
initiatives to legalize it in Argentina, among other 
countries.  
In Spain, the Organic Law 4/2015 of March 30th 
on the Protection of Citizen Security on cannabis 
cultivation is in force since July 1st, 2015. Pursuant to 
article 36, only cannabis consumption is considered a 
serious, punishable offence when committed in places 
visible to the public [8]. In response to this situation, 
cannabis social clubs (associations conceived as 
non-governmental organizations for the production 
and distribution of cannabis and its derivatives for 
recreational and/or medical purposes) are so far the 
legal alternative to growing on private property for 
personal consumption. Currently in Spain, under this 
definition, there are hundreds of cannabis social clubs 
distributed throughout the state and many others in 
process of formation [9]. In 2015, the Constitutional 
Court suspended the regional law that regulated the 
consumption and supply of these clubs in Navarre. 
The Government lodged a constitutional challenge 
against it because it was considered to invade state 
competences on penal legislation, public security and 
health. Recently, in Catalonia, a new Popular 
Legislative Initiative law has been approved. It 
regulates cannabis consumer organizations, as well as 
the cultivation and transportation of cannabis by 
these clubs. In Spain and some of its autonomous 
communities, the processes to legalize the therapeutic 
use of cannabis have also been initiated [10]. 
Among health care professionals who attend 
addictions, there is 40% who support the 
decriminalization of cannabis for personal use and/or 
its commercialization [11]. 
2.2. Principal components of cannabis 
Cannabis is a flowering plant that contains more 
than 500 different chemical compounds, including 
hundreds of different cannabinoids and 
non-cannabinoids substances. 
Non-cannabinoids compounds include a wide 
variety of terpenes and flavonoids. Terpenes are 
fragrant oils identified as the source of flavor and 
fragrance in the cannabis plant. Terpens are lipophilic 
molecules with activity in cell membranes, neuronal 
and muscle ion channels, neurotransmitter receptors, 
G-protein coupled (odorant) receptors, second 
messenger systems and enzymes which could 
contribute synergistically with cannabinoids to 
produce therapeutic actions [12, 13] Flavonoids are 
essential pigments found primarily in the flowers, 
leaves, and stems which are implicated in the unique 
smell and flavor of a cannabis strain. Similarly to 
terpenes, they may exert certain pharmacological 
activity [13]. 
The main cannabinoids are tetrahydrocanna-
binol (THC), cannabidiol (CBD), cannabinol (CBN), 
cannabigerol (CBG), tetrahydrocannabivarin (THCV), 
cannabichromene (CBC), and their respective acids 
[tetrahydrocannabinol acid (THCA), cannabidiol acid 
(CBDA), cannabigerol acid (CBGA), tetrahydrocanna-
bivarin acid (THCVA), and delta-8 tetrahydrocanna-
binol (delta-8-THC), cannabidivarin (CBGV) and 
cannabinovarin (CBNV)] [14-16]. 
2.2.1. Tetrahydrocannabinol (THC) 
The psychoactive effects of cannabis are mainly 
due to the presence of THC. THC binds to 
cannabinoid receptors CB1 and CB2, acting as a partial 
agonist. CB1 receptors are located in the central 
nervous system (cerebral cortex, hippocampus, basal 
ganglia and cerebellum), lungs, liver and kidneys. CB2 
receptors are primarily found in immune and 
hematopoietic cells. Both CB1 and CB2 are G 
protein-coupled receptors that inhibit the synthesis of 
intracellular adenosine cyclic monophosphate (cAMP) 
and thus involved in the signaling of different 
metabolic pathways). The characteristic effects of 
cannabis on behavior, nociception and thermal 
sensitivity, mood regulation, appetite and sexual 
activity, as well as antitumor and antiemetic 
properties, among others, derive from this activation. 
THC is also the component responsible for the 
reinforcing and addictive properties of cannabis 
[17-19]. 
2.2.2. Cannabidiol (CBD) 
CBD, unlike THC, does not exert direct action on 
receptors CB1 and CB2, responsible for psychoactive 
effects. CBD binds on G protein-coupled receptors 
(GPR55), serotonergic receptors (5HT-1a), opioids 
(mu and delta), and transient receptor potential 
channels [TRPV-vanilloid (TRPV1, TRPV2), 
TRPA-ankirin (TRPA1), TRPM-melastatin (TRPM-8), 
equilibrative nucleoside transporter (ENT), 




peroxisome proliferator-activated gamma receptor 
(PPAR-γ) [20]. 
CBD is mostly devoid of adverse psychoactive 
effects and abuse liability. CBD possesses anticonvul-
sant, analgesic, anti-anxiety, antiemetic, immune- 
modulating, anti-inflammatory, neuroprotective, and 
anti-tumorigenic properties [21]. CBD has been 
evaluated for the treatment of some mental disorders 
(anxiety, schizophrenia, addictions) or some types of 
epilepsy [22-24]. Early clinical results are promising in 
some treatment-resistant childhood epilepsies, which 
will have to be confirmed [22]. A CBD oral solution 
(Epidiolex®) has been approved by the US Food and 
Drug Administration in June 2018 for the treatment of 
seizures associated with two rare forms of childhood 
epilepsy (Lennox-Gastaut syndrome and Dravet 
syndrome) in patients 2 years of age and old.  
2.2.3. Cannabis/THC ratio 
The content or percentage (%) of THC and its 
ratio to cannabidiol (CBD) or THC/CBD ratio defines 
the cannabis potency and its psychoactive effects. 
High THC/CBD ratios are associated with euphoric, 
relaxing, and anxiolytic effects, while low THC/CBD 
ratios often exert sedative effects and are used as 
medical cannabis. 
2.3. Changes in the composition of cannabis 
Cannabis in the illegal market is sold as cannabis 
inflorescences (marijuana, seedless, and ditch weed). 
Sativa variety presents the highest percentage of THC, 
indica and ruderalis varieties have the higher 
percentage of CBD. Some hybrid varieties present 
high potency such as the Skunk (75% sativa, 25% 
indica), cannabis resin (hashish, grifa) and liquid 
cannabis (oil or cannabis tea). According to the latest 
European Drug Report on the analysis of seizure data 
(2006-2014), there has been a considerable increase in 
potency of the herb (8-12% THC) and resin (12-18% 
THC) [24]. These observations coincide with the 
analysis carried out by the Drug Enforcement 
Administration (DEA), with an increase in the 
percentage of THC from 4 to 12% in the last 20 years 
[25]. Similar increases in potency have also been 
documented in Australia and the Netherlands [26, 27]. 
This global trend has been mainly attributed to the 
selection and introduction of variants with a high 
content of THC and the use of intensive production 
techniques [28]. In this regard, several studies have 
associated cannabis use with a high percentage of 
THC (herb or THC extracts) with a considerable 
increase in acute toxicity, and especially with an 
increased risk of psychosis [15, 29-34]. It is important 
to note, as discussed later in the section of medical 
cannabis, that, for some years, cannabis products of 
different percentage composition of THC and CBD 
have been commercialized, so that one can get the 
desired THC and CBD percentage and adjust it to 
one’s preferences or needs, especially for medicinal 
use. This includes seeds that guarantee adjusted 
content. 
2.4. New forms of cannabis use: electronic 
cigarettes, vaporizers 
Since ancient times cannabis has been used 
orally as solid (cannabis butter,“majoun”, brownies, 
cookies or cakes) and liquid products (infusions and 
teas, "bhang", "charas", "ganja", dyes or oils). The main 
method of consumption is pulmonary inhalation 
[joints, blunts, pipes (whether made of wood; metal 
“cachimba”, "shisha”, hookah; water or bong)]. 
Recently, in the US and Europe a new form of use 
popularly known as “dabbing” has been established, 
which consists of extracting a sticky oil with a high 
content of THC (higher than 70%) (honey, dabs, wax, 
shater) using butane gas [butane hash oil (BHO)] 
through a specially designed dab rig device (nail, 
torch, carb cab and mat). In recent years, apart from 
“dabbing”, other new forms of cannabis use have 
been spread by means of electronic devices: modified 
electronic cigarettes (e-cigarettes) and vaporizers [35]. 
"Cannavaping" refers to the inhalation of smoke 
through electronic cigarettes that are capable of 
vaporizing THC-enriched e-liquids or other models 
designed exclusively for THC use (e.g. “e-joint") or 
only CBD (KanaVape®) [27]. There is also a wide 
variety of vaporizers, either portable, desktop or 
electrical. The latter are more complex devices (base, 
filling chamber, valves, bag, nozzle) which vaporize 
through hot air at an adjustable temperature. Finally, 
the vaporizer Volcano®, besides being an alternative 
to the methods of recreational consumption of THC, it 
is the only one approved as a medical device in the 
European Union (EU) and Canada [36, 37]  
2.5.Therapeutic use of cannabis: medical 
cannabis 
Medical cannabis (or medicinal marijuana) is a 
broad term that encompasses the use of cannabis for 
therapeutic purposes. As such, it includes products of 
medical cannabis and the medication of natural origin 
Sativex® that will be reviewed in this section. 
Synthetic cannabinoids approved as drugs by 
competent regulatory agencies (Marinol® or 
Cesamet®) will be reviewed in section 3.3. 
Therapeutic use of synthetic cannabinoids. 
In the Netherlands, cannabis can be purchased as 
different pharmaceutical preparations of cannabis 
flowers standardized on THC and CBD named 
"Cannabis flos” (sativa variety: Bediol® [6.5% THC, 




8% CBD-granules], Bedrobinol® [13.5% THC, <1% 
CBD], Bedrocan® [22% THC, <1% CBD]; indica 
variety: Bedica® [14% THC, <1%CBD], Bedrolite® 
[0.4% THC and 9% CBD], Bedropuur® [high THC %, 
<1% CBD available for research]) [38].  
In Canada, besides cannabis flowers 
standardized on THC and CBD (0.7-22% THC, 
0.5-13% CBD), they also have cannabis oils with 
different concentrations (1-18.3% THC, 0.2-20% CBD) 
[39].  
In Italy, from January 2017, the Government has 
put on sale standardized cannabis preparations 
(inflorescences for smoking or preparing tea or oil) 
produced by the Military Pharmaceutical Institute in 
Florence. This medicinal sativa variety of cannabis, 
called FM2 (Pharmaceutical, Military and 2 
cannabinoids) or also known as "cannabis di stato" or 
“cannabis italiana", has a THC and CBD percentage 
varying between 5-8% and 7-12%, respectively, with a 
cannabinoid profile similar to the Dutch preparation 
Bediol® and a significantly lower market price [40]. 
On the other hand, the term "medical cannabis" 
coexists with "legal medical marijuana" or “medical 
marijuana”, defined as the use of the unprocessed 
plant itself (cannabis sativa) or an extract of it to treat 
symptoms or an illness. In the USA, the medicinal use 
of marijuana is permitted for patients with serious 
medical conditions, including dozens of pathologies 
and symptoms, ranging from anxiety to insomnia, 
attention deficit hyperactivity disorder (ADHD), 
depression, arthritis and anorexia, among others. It 
can only be prescribed in the form of capsules, liquids 
and/or oils to vaporize, inhale and/or administer 
orally (infusions, tinctures, candy, cakes, cookies, 
among others) or topically (patches, creams). Some of 
the most important companies in this sector are 
BinduBotanicals, CW Botanicals, Royal Queen Seeds, 
and BioCBD+, among others. Specifically, CW 
Botanicals and Royal Queen Seeds have an entire 
plant extract of the Charlotte's variety based on CBD 
for the treatment of epilepsy and a 4% CBD oil (0.2% 
THC), respectively [41, 42], while BioCBDplus 
markets a combination of CBD and turmeric with 
anti-inflammatory effects used by athletes and also by 
patients with rheumatoid arthritis and autoimmune 
diseases [43]. It should be noted that in the US, 
medical cannabis preparations are marketed in 
multiple forms, sometimes resembling high 
consumption food products (lollypops). In relation to 
dietary supplements, the Food and Drug 
Administration (FDA) warns that no product 
containing CBD can be named as such, and expressly 
prohibits the addition of CBD in any type of food 
product [44]. It should be noted that, according to 
data published in the general press, in some USA 
states, the cannabis legal industry (medical and 
recreational) brings in more taxes than alcohol. 
In 2005, Health Canada approved nabiximol, a 
pharmaceutical preparation that comes from selected 
cannabis plants and contains a 1:1 THC/CBD ratio 
(Sativex®). It was indicated for the treatment of 
moderate or severe spasticity in multiple sclerosis and 
was later extended to treatment of 
opioid-non-responsive pain in these patients. 
Sativex® is available in many other countries, within 
the EU: Spain, France, and the United Kingdom (UK), 
among others. 
3. Synthetic cannabinoids (SCs) 
3.1. Origin and recreational use  
SCs also called cannabimetics, are a large and 
heterogeneous group of substances that are 
characterized by its acting on the same brain receptors 
as THC, and they constitute the largest group of new 
psychoactive substances (NPS) [1, 2]. According to the 
United Nations Office on Drugs and Crime 
(UNODC), out of the 739 analyzed NPS in 2016, the 
majority of them were SCs (32%) [45]. From 2008 to 
2016 the EU Early Warning System has identified 169 
new SCs (1 in 2008, 9 in 2009; 11 in 2010, 23 in 2011, 30 
in 2012; 29 in 2013; 30 in 2014; 25 in 2015 and 11 in 
2016). At the same time, there has been an increase in 
seizures [2].  
The first SCs were synthesized 25 years ago by 
academic laboratories or the pharmaceutical industry. 
Indeed, some of the names of these SCs come from the 
name of the person responsible for its synthesis, for 
example, John W. Huffman, from Clemson University 
in the USA. Subsequently, the names of many others 
have also been granted depending on the 
person/institution that synthesized them, for 
example, in the case of AM-2201 (Alexandros 
Makriyannis), HU-210 (Hebrew University), CP 
47,497 (Charles Pfizer) or WIN 55,212-2 (Sterling - 
Winthrop, Inc.). 
Currently SCs are classified according to their 
chemical structure in seven groups: naphthoylindoles, 
naphthylmethylindoles, naphthoylpyrroles, naph-
thylmethylindenes, phenylacetylindoles, cyclohexyl-
phenols, and dibenzopyrans or classical 
cannabinoids. However, the progressive identification 
of SCs of new synthesis has led to the use of new 
terms and classifications. In recent years, in many 
publications, SCs are referred to as synthetic 
cannabinoid receptor agonists (SCRA), in reference to 
their action as agonists or partial agonists on 
cannabinoid receptors, although there may be other 
mechanisms of action (e.g. the inhibition of enzymes 
that degrade natural cannabinoids). Consumption 




bans since 2009 [46, 47] and the Controlled Substance 
Act (2012) have led to successive structural changes 
and, consequently, to the classification of SCRA into 
first (JHW-018), second (AM-2201, UR-1448) and third 
generation (BB-22, 5F-PB-22, 5F-AKB-48 and STS-135), 
respectively. Later, other SCs appeared, such as 
APINACA, MDMB-FUBINACA, ADB-FUBINACA, 
MDMB-CHMICA, AB-CHMINACA and 5F-MDMB- 
PINACA, UR-144, 5F-AKB48, and ADB-CHMINAC. 
In Europe, the five SCs that were seized the most in 
2015 were ADB-FUBINACA, AB-CHMINACA, R-144, 
5F-AKB48 and ADB-CHMINACA [2]. 
According to 2015 data published by the 
European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA), approximately 64% of the 
seized SCs was in the form of herbal mixtures and 
13% in the form of processed powders in "smokable 
herbal mixtures” [2]. As epidemiological studies and 
survey data from recreational consumers show, SCs 
can be purchased in the form of powder, oily paste, 
herbal mixture or incense [48]. The powder is 
normally white but it can be of other colors. It tends to 
be packed in bags with labels that provide 
information about the composition, weight and 
purity, which specify that the content is "not suitable 
for human consumption", “for laboratory use only", 
"for technical use only". However, the most common 
form of presentation for SCs are preparations in the 
form of herbs, which are normally sold in packages of 
striking appearance that typically contain 0.4-3 grams 
of dried vegetable matter (different plant species with 
psychoactive effects) to which are added one or more 
SCs. This composition can vary even between 
different packages of the same product. Most 
packages include the warning that this is "a mixture of 
incense" that releases various scents 
(activity/workout sessions: aromatherapy, yoga, or 
meditation) and that, as well as packages that include 
powder, they are not suitable for human 
consumption. Most of them are marketed under trade 
names such as Spice, K2, Puff, Kronic, Karma, 
Voodoo, Kaos, Yucatan Fire, Smoke, Sence, Chill X, 
Highdi’sAlmdröhner, Earth Impact, Gorillaz, Skunk, 
Genie, Galaxy Gold, Space Truckin', Solar Flare, Moon 
Rocks, Blue Lotus, Aroma or Scope [49]. 
In Europe, the popular SC phenomenon has been 
partly due to the high demand for cannabis, as well as 
the continuous emergence onto the market of new SCs 
when the existing ones were subject to control 
measures. 
3.2. Pharmacology and clinical pharmacology 
of synthetic cannabinoids 
Generally, the available information on the 
pharmacology of SCs is limited. However, there is 
data in which they were studied as potential drugs. In 
the market, there is a lot of SCs of different 
compositions and varieties and there is even presence 
of several different SCs within the same product [50, 
51]. Currently, available data are derived from “in 
vitro” and “in vivo” preclinical studies, in particular 
from JWH-018 and WIN55,212-2, CP55,940 and 
HU-210 [52]. First generation SCs, as JWH-018, are 
CB1 and CB2 agonists with a higher affinity than THC 
and showed CB1-dependent reinforcing properties 
and dopamine (DA) stimulant actions [53]. Third SCs 
generation (BB-22, 5F-PB-22, 5F-AKB-48 and STS-135) 
can be even more potent as a CB1 receptor agonists 
compared to JWH-018 [54]. 
Overall, SCs are mainly pure agonists for CB1 
and CB2 receptors, and less frequently, partial 
agonists or antagonist. In addition, it has been proved 
that some of them such as WIN55,212-2, CP55,940 and 
HU-210 may also be involved in the modulation of 
GABAA, mu-opioid, serotonergic (5-HT2A) and 
dopaminergic receptors. In animal models, the acute 
administration of THC and SCs typically produces 
hypothermia, analgesia, cataplexy and reduced 
locomotive activity, as well as hypotension due to 
their activity on CB1. Anti-inflammatory, 
antiproliferative and antioxidant properties are 
attributed to CB2 [55, 56]. Regarding chronic effects 
and, especially, tolerance, they vary depending on the 
SC administered, age, dose, route of administration, 
and duration of exposure. Based on all these factors, 
the repeated administration of some SCs has been 
linked to deficits in short-term and working memory, 
as well as alterations in the process of discrimination 
and implication of anxious states and the response to 
stress [57]. 
As for the vast majority of NPS, there are no 
clinical trials specifically designed to evaluate their 
human pharmacology. At least there has been 
published a dozen studies that included "semi- 
experimental" administration (self-administration) of 
one or more SCs for their detection and quantification 
in order to validate analytical methods. In some of 
these studies, plasma and/or urinary concentrations 
and, occasionally, subjective effects have been 
described. This is the case for Spice2, Smoke, K2 
Standard, K2 Citron, Summit, AM-694, AB-001 and 
AM2201, JWH-018, and JWH-073 [58-64]. Peak plasma 
concentrations were reached approximately 10 
minutes after intrapulmonary administration 
(smoked), the main effects for all of them being 
increased heart rate, dry mouth, eye redness and 
alterations in mood and perception, similar to what 
was observed after the experimental administration of 
THC. The first pharmacokinetic, neurocognitive and 
subjective data on JWH-018 in humans have been 




recently published [65, 66]. Despite the limitations of 
the study (small sample (n=6) and lower doses than 
those used for recreational purposes) the results 
suggest similar pharmacokinetics to THC. The study 
analyses 2g and 3g of JWH-018 smoked in a pipe and 
for both doses mean peak plasma concentrations were 
reached approximately 5 minutes after administration 
[65]. 
3.3. Therapeutic use of synthetic cannabinoids 
Despite the fact that since ancient times the 
medicinal properties of cannabis and its use in 
numerous ailments have been widely documented, it 
wasn’t included as such in the American and 
European pharmacopoeia until the end of the 19th 
century. It was illegalized by the International Opium 
Convention of 1925 and the Marijuana Tax Act of 
1937. Even though they were not specifically enacted 
to criminalize its medicinal use, it negatively affected 
its use in medical terms. Several decades later, in 1964, 
the chemical structure of THC was discovered and 
synthesized for the first time (Professor Raphael 
Mechoulam, Hebrew University of Jerusalem) [67]. 
Thereafter, and coinciding with its progressive 
decriminalization, the interest for its potential 
therapeutic effects resurged. In the 90’s, the discovery 
of several compounds: anandamide (N-arachidonoyl-
ethanolamine or AEA), 2-arachidonoylglycerol 
(2-AG), arachidonic acid and its derivatives gave a 
name to the endocannabinoid system. Its involvement 
in the analgesia, cognition, and memory 
processes/pathways, locomotive activity, appetite, 
vomiting and immune function significantly 
increased biomedical research and the therapeutic 
potential of cannabis. However, it was not until 1985 
that the FDA approved the first cannabinoid 
drug—dronabinol (synthetic THC, Marinol®) and 
nabilone (a synthetic THC, Cesamet®) for the nausea 
and vomiting caused by chemotherapy as side effects 
in patients refractory to other antiemetic treatments. 
Later, in 1992, the indication of dronabinol was 
extended to the treatment of patients suffering from 
HIV-associated anorexia. Further on, other drug 
regulatory authorities approved the 
commercialization of other cannabinoid drugs. As 
mentioned, in 2006, the natural preparation Sativex® 
and rimonabant (Acomplia®) were approved in 
Canada by the European Medicine Agency (EMA). 
Rimonabant was the first cannabinoid indicated in 
patients with overweight and obesity for reducing 
appetite but it was taken off the market in 2009, after 
detecting a significant increase in the risk of mental 
disorders, and the notification of five cases of suicide 
[68]. Currently, commercialized cannabinoid drugs 
differ depending on the country. In the UK and the 
USA, dronabinol and nabilone, while nabiximols can 
be prescribed in many countries of the European 
Union, and in Canada, as already mentioned [69, 71]. 
In the past 10 years, different cannabinoids have 
been investigated in preclinical studies and even in 
advanced stages of clinical studies [Otenabant® 
(CP-945,598) and Taranabant® (MK-0364), both 
similar to rimonabant, levonantradol (Nantrodo-
lum®), andajulemic acid (AJA; CT3)]. However, due 
to the lack of efficacy and/or toxicity, finally none of 
them has been approved for human use. 
Other potentially effective cannabinoids for the 
treatment of different diseases are currently under 
research/approval. Echopharma is developing 
Namisol® (98% pure, natural THC) for multiple 
sclerosis, Alzheimer's disease and chronic pain [72, 
73]. GW Pharmaceuticals has Epidiolex © (98% CBD), 
which has been already classified by the FDA as an 
orphan drug for Lennox-Gastaut and Dravet 
syndromes (severe myoclonic epilepsy of infancy, or 
polymorphous epilepsy) and tuberous sclerosis [21, 
69, 74].Different molecules in the process of 
development have also fallen into the same category: 
i) GWP42006 [Cannabidivarin (CBDV)] for epilepsy; 
ii) GWP 42002 for glioma; iii) GWP42003 for neonatal 
hypoxic-ischemic encephalopathy, schizophrenia and 
glioma; iv) GWP42004 for diabetes type 2 [75]. The 
potential therapeutic effect of CBD is also being 
evaluated for the treatment of Parkinson's disease, 
anxiety disorder, multiple sclerosis, substance use 
disorder, post-traumatic stress disorder, 
graft-versus-host disease, among others [16, 21, 22, 
76]. In addition, they are also being studied in several 
neurodegenerative, psychiatric, oncological, 
ophthalmological and dermatological diseases, 
among others [77]. 
3.4. Adverse reactions and intoxications 
caused by synthetic cannabinoids 
3.4.1. Adverse reactions and intoxications caused by 
the recreational use of synthetic cannabinoids 
Information about adverse reactions and 
intoxications associated with the consumption of SCs 
is limited mainly because it is difficult to find 
biological matrices in acute care areas (currently there 
are no commercial fast diagnostic kits) and because of 
the constant emergence of new SCs. Even so, the 
general toxicity profile of SCs is presumably similar to 
high-potency cannabis characterized by more potent 
and long-lasting effects [50].  
In this regard, there are epidemiological and 
toxicological data coming from surveys, poison 
centers, intoxication registers, clinical cases and case 
series. Data reported suggest that severe adverse 




reactions and fatal intoxications are much more 
common with SCs than with cannabis probably linked 
to high potency and the unintentionally high doses 
used [50, 51, 83, 84]. 
According to notifications received by American 
poison centers, adverse reactions associated with the 
use of SCs increased by 330% in early 2015 
(January-April), the most frequently reported 
symptoms being agitation, nausea, tachycardia, 
drowsiness/lethargy, vomiting and confusion [78]. 
These data coincide with cases of acute poisoning in 
patients seen in the Emergency department, who 
typically have psychiatric (agitation, anxiety, panic 
attacks, psychotic symptoms, hallucinations), 
cardiovascular (tachycardia, hypertension and chest 
pain), gastrointestinal (nausea, vomiting) and 
neurological symptoms (decreased level of 
consciousness) [79-82]. Most of them are quickly 
solved (6-24 hours) with symptomatic medical 
treatment. However, among serious and 
life-threatening complications, the following have 
been described: myocardial infarction, transient 
ischemic attack, acute kidney injury, generalized 
tonic-clonic seizures, psychosis, and suicidal ideation.  
SCs in comparison to cannabis have been 
described have high-risk of developing psychosis 
especially in young individuals [50, 51, 83, 84]. At this 
respect, findings from brain imaging studies suggest 
that SC could produce alterations/changes in brain 
regions that are often implicated in psychosis [50]. 
Importantly, evidence indicates that SCs use impairs 
executive functions [51, 85]. 
The SCs that were detected the most in cases of 
acute poisoning correspond to derivatives of JWH, 
and to a lesser extent, of XRL-11, ADB-PINACA, 
AM-2201, MAM-2201, 5F-PB-22, UR-144, PB-22, 
AM-2233, AM-694, NNEI, BB-22, CP-47, 497-C8 and 
5F-ADB. In addition to outbreaks occurred in Europe, 
clinical patterns affecting dozens of SC users have 
been recently described in areas of American cities 
like New York [86]. 
In the latest and largest online survey about drug 
use [Global Drug Survey (GDS)], 12.5% of daily and 
weekly SC users have required urgent medical 
treatment (3.5% of respondents), posing a 30-fold 
higher risk compared to cannabis users. According to 
these data, more than half of daily and weekly SC 
users talk about withdrawal, which is described as 
being similar to the one from cannabis [87-89]. Based 
on the available limited evidence, it is suggested that 
SCs, in comparison with cannabis, have greater 
cardiac and neurological toxicity. 
The EMCDDA due to the reported high toxicity 
of some SCs, has issued several warnings on the 
subject. In the last one, published in February 2016, 
the SC MDMB-CHMICA has been linked to 13 deaths 
and 23 non-fatal intoxications [90-95]. 
3.4.2. Adverse reactions and intoxications caused by a 
synthetic cannabinoids in clinical development: the BIA 
10–2474 case 
Severe adverse reactions of currently marketed 
pharmaceutical cannabinoids have not been recorded. 
The adverse reactions most often described are mild 
to moderate, with dizziness, fatigue, ataxia, and 
difficulty concentrating.  
However, in 2016, the emergence of several very 
serious adverse reactions was reported following the 
experimental administration of a cannabinoid drug in 
phase I study in Rennes (France). Subsequently, it was 
known that it was caused by BIA 10-2474 (Bial 
Pharmaceutical®, Portugal), which is an inhibitor of 
fatty acid amide hydrolase (FAAH) that increases the 
concentration of anandamide in the central nervous 
system and peripheral tissues. Previously, this drug 
had been administered in a single dose (0.25-10 mg) 
and multiple doses (2.5 - 10 mg/day for 10 days) to 
successive cohorts of up to 84 volunteers without 
observing adverse reactions. Between the 5-7th day of 
administration of 50 mg/day (n=6), 4 volunteers had 
clinical neurological manifestations such as headache, 
cerebellar ataxia, memory impairment, altered level of 
consciousness, diplopia, hemiparesis and amnesia. 
Brain death was observed in one of them, two 
recovered with sequelae (one subject with residual 
memory impairment, and the other one with residual 
cerebellar syndrome), and one recovered without 
sequelae. The nuclear magnetic resonance imaging 
study revealed irreversible brain damage, 
hemorrhage and necrosis [96]. According to the 
research carried out, it has been suggested that several 
factors might have contributed to the dramatic event, 
such as low drug specificity and reversibility (high 
inhibition), impact on the immune system, dose 
calculation, cumulative toxicity, off-target effects, 
drug impurities, and human error [97]. Currently, the 
mechanisms involved in the neurotoxicity of BIA 
10-2474 are unknown exactly, but experimental 
studies are trying to elucidate the possible etiology 
[98-99]. A recent paper in human cells using an 
activity-based protein profiling, suggests that BIA 
10-2474, besides acting as an irreversible FAAH 
inhibitor, could alter neuronal lipid metabolism by 
inhibition of PNPLA6, an off-target protein. It is 
known from in vitro studies that the drug inhibits 50% 
of FAAH activity at the dose of 0.25 mg, and 100% at 
the dose of 5 mg, and seems less selective than other 
inhibitors in development. Although, right now, there 
is no causal relationship and there are many 
unknowns to be solved, it has been postulated that the 




risk of cerebral toxicity could depend on the biological 
species being studied. This is the reason why toxicity 
was not observed in preclinical studies performed in 
rats and mice [100]. 
The FDA, in collaboration with the EMA and the 
French National Agency for Medicines and Health 
Products Safety (Agence Nationale de Sécurité du 
Médicament et des Produits de Santé, ANSM), has 
issued a note clarifying that the toxicity presented by 
BIA 10-2474 cannot be extended to other FAAH 
inhibitor drugs that are in experimental phase [101]. 
There are currently several laboratories that are 
investigating in the same vein. Right now, there isn’t 
any marketed endocannabinoid drug acting 
specifically through this pathway.  
4. Conclusions 
The use of cannabis and, in general, 
cannabinoids has spread in recent years. It should be 
noted that the synthetic cannabinoids and the medical 
cannabis phenomena have opened the debate on their 
legalization in recreational and, especially, medical 
terms. To this day, both aspects continue to be a topic 
of great interest in public health and clinical medicine.  
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